A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGCETACOPLAN IN PATIENTS WITH C3 GLOMERULOPATHY OR IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS

Registry ID

APL2-C3G-310

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

APELLIS PHARMACEUTICALS, INC

Start date

2023-08-11

Completion date

2024-12-12

Last update

2022-05-18

Conditions

• GLOMERULOPATHY

Related clinical trials

• AN OPEN-LABEL, NON-RANDOMIZED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF IPTACOPAN (LNP023) IN C3 GLOMERULOPATHY OR IDIOPATHIC IMMUNE-COMPLEX-MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IPTACOPAN (LNP023) IN COMPLEMENT 3 GLOMERULOPATHY

View on source registry